Morepen Laboratories Enters US Prescription Generics Market with Desloratadine Launch

manufacturing-news
Image Courtesy: Pixabay

Morepen Laboratories Limited has entered the US prescription generics market with the launch of its first prescription generic product, Desloratadine Tablets USP, 5 mg, in 100-count and 500-count packs. The product will be distributed in the US through the company’s wholly owned subsidiary, Morepen Bio Inc.

The launch builds on Morepen’s established presence in the US market as a supplier of Desloratadine active pharmaceutical ingredient (API). Having supplied the API to the US for several years, the company is now extending its participation in the pharmaceutical value chain to finished-dosage formulations and product distribution.

Sanjay Suri, Managing Director, Morepen Laboratories Limited, said, “Our long-standing API relationships in regulated markets provide a strong foundation for Morepen’s next phase of growth. Alongside our expanding CDMO business, we are selectively extending our capabilities into finished-dosage development and U.S. distribution. This reflects our strategy to build a more integrated, R&D-led pharmaceutical business with sustainable, long-term growth opportunities.”

The prescription generics launch follows the company’s earlier introduction of over-the-counter (OTC) products in the US market. In a separate development, Morepen has submitted its first Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA) for Sitagliptin Phosphate Tablets USP in 25 mg, 50 mg and 100 mg strengths. The application is currently under regulatory review.

The ANDA submission marks progress in the company’s formulation development, analytical science and regulatory capabilities. It also supports Morepen’s plans to expand its finished-dosage portfolio in regulated international markets. Going forward, the company intends to pursue additional US prescription generic filings and distribution opportunities in areas where its established API manufacturing and pharmaceutical research and development capabilities can support product development and commercialisation.

Morepen is also evaluating selected opportunities in high-potency APIs (HPAPIs) and oncology. Any such expansion will be assessed based on development feasibility, regulatory requirements and prevailing market conditions. The move into prescription generics represents an extension of Morepen’s pharmaceutical business beyond its established API operations. By combining its experience in API manufacturing with formulation development, regulatory expertise and US distribution capabilities, the company aims to build a more integrated pharmaceutical business and broaden its presence in international markets.

Morepen Laboratories Limited is a publicly listed Indian pharmaceutical and healthcare company with operations spanning active pharmaceutical ingredients (APIs), contract development and manufacturing organisation (CDMO) services, formulations and healthcare products. The company serves customers in domestic and international markets.